The New England Journal of MedicineOverall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Pivotal Role of Adjuvant Osimertinib in EGFR-Mutated NSCLC Survival

A groundbreaking phase 3 trial reveals the significant impact of adjuvant osimertinib on overall survival rates in patients with resected, EGFR-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC).

• The ADAURA trial compared adjuvant osimertinib therapy to placebo in patients with resected, EGFR-mutated, stage IB to IIIA NSCLC.
• The trial was a phase 3, double-blind study with a 1:1 patient assignment to either osimertinib or placebo.
• The primary end point was investigator-assessed disease-free survival among patients with stage II to IIIA disease.
• A total of 682 patients were randomized, with 339 receiving osimertinib and 343 receiving placebo.
• Among patients with stage II to IIIA disease, the 5-year overall survival was 85% in the osimertinib group and 73% in the placebo group.
• In the overall population, the 5-year overall survival was 88% in the osimertinib group and 78% in the placebo group.
• Adjuvant osimertinib demonstrated a safety profile consistent with the primary analysis.